Recently, AlphaMol received milestone payments from both Shanghai Pharma and Salubris Pharma for the co-developing orphan GPCR drug discovery pipeline.

The paper enttiled "Advancing Drug Discovery via Artificial Intelligence" by the team member of AlphaMol has been in the list of Highly Cited Article (HCA). The total citation of this work is over 310 times by April 2023. 

By resolving the 3D structure of this important target Panx2 coupled with computational simulations, the molecular mechanisms were illuminated which could guide Panx2-based drug discovery for brain cancer.  

AlphaMol attended BioEuro 2022 in Leipzig, Germany and made collaborations with different partners.

The cofounders of AlphaMol Dr. Horst Vogel and Dr. Shuguang Yuan are among World’s Top 2% Scientists in the 2022 list. 

AlphaMol presented in the international GPCR conference

The XXVIII Symposium on "Bioinformatics and Computer-Aided Drug Discovery--Emerging Challenges and Opportunities for In Silico Drug Discovery " was held online on May 24 - 26.

AlphaMol scientists developed a new computational algorithm for physical property predictions.

AlphaMol Science made breakthrough in orphan GPCR new drug discovery via innovative computational methods.